OPKO Health, announced that the US Food and Drug Administration (FDA) has approved the company’s point-of-care Sangia Total Prostate Specific Antigen (PSA) Test using the Claros 1 Analyzer. The ...
Extra value: One year of free online updates included with this productThere are today at least 374 targeted molecular therapies known to affect more than 244 specific intracellular signaling pathways ...
MIAMI, Feb. 01, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s point-of-care Sangia Total Prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback